426 related articles for article (PubMed ID: 26754924)
21. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
22. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
23. Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database.
Tengstrand M; Star K; van Puijenbroek EP; Hill R
Drug Saf; 2010 Aug; 33(8):653-8. PubMed ID: 20635823
[TBL] [Abstract][Full Text] [Related]
24. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
25. Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance.
Gadroen K; Straus SMJM; Pacurariu A; Weibel D; Kurz X; Sturkenboom MCJM
Vaccine; 2016 Sep; 34(41):4892-4897. PubMed ID: 27577558
[TBL] [Abstract][Full Text] [Related]
26. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.
Sultana J; Scondotto G; Cutroneo PM; Morgante F; Trifirò G
Front Pharmacol; 2020; 11():315. PubMed ID: 32226387
[TBL] [Abstract][Full Text] [Related]
28. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
29. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis.
Star K; Iessa N; Almandil NB; Wilton L; Curran S; Edwards IR; Wong IC
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):440-51. PubMed ID: 23234587
[TBL] [Abstract][Full Text] [Related]
30. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring.
Kuemmerle A; Dodoo AN; Olsson S; Van Erps J; Burri C; Lalvani PS
Malar J; 2011 Mar; 10():57. PubMed ID: 21388536
[TBL] [Abstract][Full Text] [Related]
31. Pharmacovigilance activities in ASEAN countries.
Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
[TBL] [Abstract][Full Text] [Related]
32. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
Kalaiselvan V; Sharma S; Singh GN
Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
[TBL] [Abstract][Full Text] [Related]
33. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
Wallerstedt SM; Brunlöf G; Sundström A
Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
[TBL] [Abstract][Full Text] [Related]
34. Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East.
Mlotshwa CRN; Burger JR; Vorster M; Rakumakoe DM; Cockeran M
Curr Drug Saf; 2022; 17(3):225-234. PubMed ID: 34749625
[TBL] [Abstract][Full Text] [Related]
35. Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase(®).
Aldea Perona A; García-Sáiz M; Sanz Álvarez E
Drug Saf; 2016 Jan; 39(1):69-78. PubMed ID: 26620206
[TBL] [Abstract][Full Text] [Related]
36. Disease-related adverse events following non-live vaccines: investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase.
Roberto G; Zanoni G
Vaccine; 2014 May; 32(26):3328-35. PubMed ID: 24291198
[TBL] [Abstract][Full Text] [Related]
37. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
38. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
[TBL] [Abstract][Full Text] [Related]
39. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
40. The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan.
Wakao R; Lönnstedt IM; Aoki Y; Chandler RE
Drug Saf; 2021 Jun; 44(6):681-697. PubMed ID: 33837924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
